Show Summary Details
Page of

Asymptomatic hyperuricaemia: to treat or not to treat? 

Asymptomatic hyperuricaemia: to treat or not to treat?
Asymptomatic hyperuricaemia: to treat or not to treat?

Thomas Bardin

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 June 2021

Asymptomatic hyperuricaemia is a frequent finding and evidence is growing that it could be an independent cardiovascular risk marker. Recent studies challenge the dogma not to treat asymptomatic hyperuricaemia. However, no urate-lowering drug has been approved for the management of asymptomatic hyperuricaemia in Western countries, because the lack of large randomized control trials precludes assessment of benefits. Asymptomatic hyperuricaemia should lead to lifestyle changes and promote the search for cardiovascular risk factors amenable to therapy, in order to lower the hazards of cardiovascular disease and mortality.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.